The Deputy editor of JAMA provides a series of recommendations on maintaining clinical trial integrity during the COVID-19 pandemic.
JAMA emphasises the need for creative thinking and persistence in maintaining clinical trials.
The recommendations include considerations of risk and benefit in continuing a trial, ensuring patient health and safety, collection of outcome data, delivery of the intervention and maintaining trial staff safety.